Roche’s Renal Anemia Studies Show Benefits Of CERA Once-Monthly Dosing
This article was originally published in The Pink Sheet Daily
Executive Summary
The continuous erythropoietin receptor activator is to be marketed under the trade name Mircera.
You may also be interested in...
J&J, Roche Data Show Dosing Benefit In Treating Anemia With Procrit, Mircera
J&J releases data for the first time on treatment of hemoglobin levels with Procrit every two weeks.
J&J, Roche Data Show Dosing Benefit In Treating Anemia With Procrit, Mircera
J&J releases data for the first time on treatment of hemoglobin levels with Procrit every two weeks.
Aranesp “Complete Response” Letter Seeks Additional Clinical Data On Monthly Dosing
Amgen hopes to respond to FDA request with already collected data.